Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
Fiche publication
Date publication
août 2017
Journal
Annals of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M,
Lien Pubmed
Résumé
To identify biomarkers associated with the development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab (NTZ).
Mots clés
Biomarkers, blood, Blood Proteins, biosynthesis, Gene Expression, drug effects, Humans, Immunologic Factors, blood, Leukoencephalopathy, Progressive Multifocal, blood, Matrix Metalloproteinase 9, biosynthesis, Multiple Sclerosis, Relapsing-Remitting, blood, Natalizumab, adverse effects, Vascular Endothelial Growth Factor A, biosynthesis
Référence
Ann. Neurol.. 2017 Aug;82(2):186-195